Pharmacokinetics of lorazepam in critically ill neonates with seizures

J Pediatr. 1992 Mar;120(3):479-83. doi: 10.1016/s0022-3476(05)80925-4.


Pharmacokinetic data were evaluated in 10 term neonates with seizures after intravenous administration of lorazepam, 0.05 mg/kg or 0.1 mg/kg. All seizure activity ceased, with no adverse effects. Pharmacokinetic data revealed a decreased volume of distribution and clearance, and a prolonged half-life in comparison with data from older children and adults. These findings are consistent with physiologic differences in the neonate.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Critical Illness
  • Humans
  • Infant, Newborn / metabolism*
  • Injections, Intravenous
  • Lorazepam / pharmacokinetics*
  • Lorazepam / therapeutic use
  • Seizures / drug therapy*
  • Seizures / metabolism


  • Lorazepam